Page 1,609«..1020..1,6081,6091,6101,611..1,6201,630..»

Teen Suffering From Type 1 Diabetes Receives Artificial Pancreas … – CBS Miami

Posted: April 11, 2017 at 3:40 pm


CBS Miami
Teen Suffering From Type 1 Diabetes Receives Artificial Pancreas ...
CBS Miami
A Connecticut teenager is making medical history. She's one of the first in the country to receive a so called artificial pancreas.

and more »

Read the original here:
Teen Suffering From Type 1 Diabetes Receives Artificial Pancreas ... - CBS Miami

Posted in Diabetes | Comments Off on Teen Suffering From Type 1 Diabetes Receives Artificial Pancreas … – CBS Miami

Bart Starr returns to Tijuana for stem cells – USA Today

Posted: April 10, 2017 at 7:43 am

A stroke left him struggling to walk, but the former NFL quarterback has improved after stem cell treatments in Moscow, Kazakhstan and Mexico, plus regular workouts.

Former NFL quarterbacks Bart Starr, left, and John Brodie met last week in San Diego.(Photo: Brent Schrotenboer, USA TODAY Sports)

SAN DIEGO Wearing a sporty black Green Bay Packers polo shirt, Bart Starr got off of a private jet here last weekand walked into the California sunshine.

This was quite a feat. Starr, 82, had suffered two strokes and a heart attack in 2014, followed by a bronchial infection that nearly killed him in 2015 and then a broken hip that put him back in a wheelchair inDecember.

Just a few weeks ago, the legendary former Packers quarterback even underwent surgery to remove stones from his bladder.

Yet here he was again, on his feet and smiling after flying in for another round of experimental stem cell treatments 20 miles south of here, in Tijuana, Mexico.

Three times, Starr interjected when asked by USA TODAY Sports about his visits here since June 2015.

Were really looking for big things to happen with this visit because this is probably the healthiest Barts been in two years, said Cherry Starr, Barts wife.

Cherry Starr believes her husband has bounced back from his health setbacks with help from these treatments, the same kind of treatments received by two other famous stroke victims: hockey great Gordie Howe and former NFL MVP quarterback John Brodie.

USA TODAY

Fetal stem cells and the sports heroes they revitalized

The treatments involve a combination of stem cells derived from donated bone marrow and fetal brain tissue. They are manufactured by a company in San Diego, Stemedica, but they are not approved for use in the USA.

To gain such approval, they first would have to pass years of expensive tests on their safety and effectiveness.

But Brodie, 81, Starr and Howe, who died in June, didnt believe they had time to wait. They also believed they had little to lose by going to Mexico, where the company has said its more cost-effective to have its products tested than in the USA. Stemedica ships the cells to a sleek, modern clinic in an old, run-down part of Tijuana, not far from various dental clinics and a taco restaurant.

When I first went down there, I didnt really know what to expect, Cherry Starr said Thursday after returning home to Alabama. I thought,`Oh my gosh, what are we getting into? when we were driving through town. But its a lovely, lovely facility.

Clinica Santa Clarita in Tijuana has had about 250 patients take part in its clinical trial over the past two years. Patients are often charged for these experimental treatments, which cost $30,000. Bart Starr also paid for his treatment, Cherry said.

His treatment involved an injection of fetal-derived neural cells into his spine last week, followed by an injection of bone marrow-derived mesenchymal cells into his arm the next day.

Afterward, Cherry Starr said everything went absolutely great but that it was too early to notice any possible effects. Bart Starr, a Pro Football Hall of Famer, can walk slowly and usually with help at his sides. His speech also is limited, but its still a big improvement from being wheelchair-bound and barely able to feed himself after his stroke two years ago.

Stem cells, wow! said Brodie, who greeted Starr here Tuesday and is a former rival of Starrs as quarterback of the San Francisco 49ers.

USA TODAY

After stem cell treatments, Bart Starr ready for triumphant return to Lambeau Field

American stem cell experts stress caution about such treatments, either in the USA or especially in other countries where safety and effectiveness standards might not be as strict. For example, its not known how much Starr, Brodie or Howe improved on their own through natural healing or physical therapy.

Larry Goldstein, a stem cell expert and professor at the University of California San Diego, said it takes at least five to 10 years to test whether such treatments really work. In the meantime, few stem cell treatments are approved for use in the USA, though many American clinics have been offering legally and scientifically questionable stem cell treatments derived from a patients own fat or bone marrow.

Stemedicas stem cells are different than these because they are derived from donors and are replicated in a lab. They are considered unapproved biological drugs in the USA.

There is definitely a wild west of clinics in the U.S. and outside the U.S. offering unproven treatments of stem cells, Goldstein told USA TODAY Sports in June.

USA TODAY

Brett Favre shares special moment with Bart Starr at Lambeau Field

Stemedica is working toward approval by the U.S. Food and Drug Administration, including with a clinical trial in Toledo for traumatic brain injury patients. It involves bone marrow-derived cells and is part of the Gordie Howe Initiative, named after perhaps the most famous stem cell patient in America. Before his death at age 88, his family credited the Tijuana treatments with boosting the last year and a half of his life after his stroke.

On Aug. 29, a subsidiary of Stemedica announced that data from a separate, pre-clinical study showed that its bone marrow-derived stem cells improved heart function after heart attacks.

Weve always known that our stem cells exhibit unique qualities and characteristics, and were very proud of what people call the `anecdotal evidence coming from patient testimonials, said Dave McGuigan, Stemedicas vice president for marketing and business development. But now that we can give the academic and scientific community statistical evidence to go alongside the anecdotal meaningful evidence, that can only help add to the Stemedica story.

Follow sports reporter Brent Schrotenboer on Twitter@Schrotenboer. E-mail: bschrotenb@usatoday.com

See more here:
Bart Starr returns to Tijuana for stem cells - USA Today

Posted in Alabama Stem Cells | Comments Off on Bart Starr returns to Tijuana for stem cells – USA Today

Pioneering work on stem-cell therapies at UW deserves state … – The Seattle Times

Posted: April 10, 2017 at 7:41 am

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine, scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

IF you have a heart attack, hopefully youll survive. But your body will be forever changed. The worlds best doctors cant undo the damage; instead, drugs and devices will help you live with a heart whose function too often dwindles.

The body cannot replace muscle cells that die in heart attacks maladies that help make heart failure the No. 1 global cause of death and our nations biggest health care expense. These patients face daily medication, decreased energy and, for the lucky 0.1 percent, the ability to qualify for an extraordinarily costly heart transplant and anti-rejection medication that also leaves them more vulnerable to other diseases.

Thanks to medical advances, heart failure has become a chronic condition that people are now managing for decades. The same is true for diabetes, kidney disease and arthritis. But with that longevity comes a tether to drug regimens whose costs rise seemingly at whim.

Dr. Charles Murry is interim director of UW Medicines Institute for Stem Cell and Regenerative Medicine.

These chronic diseases are a major reason that health-care costs hold center stage in Americans consciousness.

Amid our collective uncertainty, medical science offers one path of relief. Specifically, the engineering of human cells and tissues to restore vitality to poorly functioning organs.

The medical conditions named above share a common root not addressed by todays best care: The body is missing a population of cells that do critical work. If we could restore that population, we could cure many chronic diseases.

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM), scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

This year, we also seek a first-time investment from our state Legislature.

Weve pioneered techniques to grow unlimited human heart muscle cells in the lab. We were the first to transplant these cells into injured hearts and repair the injury with new tissue growth. UW Medicine will begin first-in-human tests of these cells in Seattle in 2019.

If this one and done treatment prevents heart failure in even the sickest 10 percent of heart-attack patients, our nation could save a staggering $3.5 billion per year in health-care costs. More importantly, these patients will lead longer, healthier, more productive lives.

Other ISCRM scientists are pursuing a gene therapy for muscular dystrophy, a devastating illness that often strikes young boys. The therapy, tested in Labrador puppies that were paraplegic as a result of the same, naturally occurring muscle-wasting disease, had the dogs leaping and frolicking in just weeks. A clinical trial is planned for 2018.

We are similarly probing therapies for cancer, kidney failure, diabetes and Alzheimers. And were doing this with the Northwests entrepreneurial spirit: In the past decade, ISCRM has patented 250+ discoveries with commercial potential and started 20 companies.

Legislatures in at least 11 other states, including California, New York, Wisconsin, Minnesota and Maryland, have invested cumulative billions in regenerative medicine. Most of that funding has gone to university-based research centers like ours.

To this point there has been no state investment in ISCRM. Nevertheless we have built a world-class program with federal grants and private philanthropy. But those dollars come in boom-and-bust cycles, and what we need now is stable funding to maintain competitiveness.

For this reason, the UW seeks $6 million in operating funds from the Legislature, starting with the next biennium, to recruit and retain top scientists, fund promising results at early stages, and train young researchers and clinicians.

We are grateful, at this juncture, that the state Senate included us in its initial budget.

We ask all legislators to invest in the health of our residents and in the promise of what weve accomplished so far. With stem-cell biology, we are ready to rebuild solid tissues like the heart and potentially cure our nations greatest cause of death and health-care expense.

Clinical success will make Washington a destination for heart repair and other regenerative therapies. This race is ours to lose.

Excerpt from:
Pioneering work on stem-cell therapies at UW deserves state ... - The Seattle Times

Posted in Cell Medicine | Comments Off on Pioneering work on stem-cell therapies at UW deserves state … – The Seattle Times

Diabetes fatalities may be far more common than we thought – Omaha World-Herald

Posted: April 10, 2017 at 7:40 am

Nearly four times as many Americans may die of diabetes as indicated on death certificates, a rate that would bump the disease up from the seventh-leading cause of death to No. 3, according to estimates in a recent study.

Researchers and advocates say that more precise figures are important as they strengthen the argument that more should be done to prevent and treat diabetes, which affects the way sugar is metabolized in the body.

"We argue diabetes is responsible for 12 percent of deaths in the U.S., rather than 3.3 percent that death certificates indicate," lead study author Andrew Stokes of the Boston University School of Public Health said in an interview.

About 29 million Americans have diabetes, according to the Centers for Disease Control and Prevention. There are two forms of the disease: Type 1, in which the pancreas makes insufficient insulin, and the more common Type 2, in which the body has difficulty producing and using insulin.

Using findings from two large national surveys, the study looked mainly at A1C levels (average blood sugar over two to three months) and patient-reported diabetes. In the latest study, researchers compared death rates of diabetics who had participated in these surveys to information on their death certificates.

The authors also found that diabetics had a 90 percent higher mortality rate over a five-year period than nondiabetics. This held true when controlling for age, smoking, race and other factors.

"These findings point to an urgent need for strategies to prevent diabetes in the general population. For those already affected, they highlight the importance of timely diagnosis and aggressive management to prevent complications, such as coronary heart disease, stroke and lower-extremity amputations," Stokes said.

"We hope a fuller understanding of the burden of disease associated with diabetes will influence public authorities in their messaging, funding and policy decisions, such as taxation of sugar-sweetened beverages and use of subsidies to make healthy foods more accessible," he said.

When they embarked on the study, the investigators were curious about two findings from earlier research. The first was a higher obesity rate and shorter life expectancy among Americans than Europeans. (The researchers already knew that obesity and diabetes were related.) The second revelation was a rise in deaths by any cause among middle-aged white Americans.

"We tried to piece together causes of mortality in the U.S., looking closer at diabetes, which we knew was underreported," Stokes said.

Mortality rates attributed to diabetes are imprecise largely because death results from both immediate and underlying causes, and not every one of them gets recorded. For example, cardiovascular disease might be recorded as the cause of a person's death even though that disease may have been caused by diabetes.

Further challenging the task of identifying cause of death is that diabetics have a long history of problems before serious complications occur.

"When diabetes started 10 to 30 or more years before a patient died, the disease may not be in the forefront of the attending physician at time of death," explains Catherine Cowie, an epidemiologist at the National Institute of Diabetes and Digestive and Kidney Diseases. And there are no clear guidelines about which conditions should be cited as cause of death.

Detailed electronic medical records may help pinpoint the primary cause. "But still, it's hard [to get the full picture] in this day and age when health care for diabetics is divided between different practitioners," she said.

She advises patients to report their diabetes to all their health providers, whether they are having complications at the time or not.

"We've been trying to promote healthy lifestyle to prevent diabetes and complications for a long time. This includes paying attention to 'the ABCs,' which are to bring down A1C, blood pressure and cholesterol. But I think this [study] is new evidence that it's important to focus on these things. It's more data to show what diabetes can lead to," Cowie says.

In 2016, diabetes accounted for about $1.04 billion in National Institutes of Health funding, compared with about $5.65 billion spent on cancer research. Having a better gauge on the mortality figures could have an effect on research dollars, said Matt Petersen, managing director of medical information for the American Diabetes Association.

But the true death rate means only so much.

"What's most important is why it is and what we can do about it. The goal of research is prevention and, if possible, cure. Short of uncovering a cure, key is figuring out how do we best treat it and reduce complications," Petersen said.

For Type 2 diabetes, new drugs that work in combination and in different ways to address differing patient cases have rolled out in just the past two years. Healthy lifestyle choices can also affect outcomes.

"So I think the public should hear [that] yes, diabetes can be deadly, but that we have the ability to reduce the chance for this disease," Petersen says. "And for those who have diabetes, we can treat it well and reduce the risk for debilitating and deadly complications."

See more here:
Diabetes fatalities may be far more common than we thought - Omaha World-Herald

Posted in Diabetes | Comments Off on Diabetes fatalities may be far more common than we thought – Omaha World-Herald

Free Diabetes Classes at Holmes Chapel, Start Tuesday – Monticello Live

Posted: April 10, 2017 at 7:40 am

Search

CLASSIFIEDS

OBITUARIES

SCHOOL LUNCHES

LOCAL WEBSITES

Rays

Corner Express (O&M Oil Co.)

Luckys Of Monticello

Union Bank 1

Mullis Insurance

Clearview

Walmart

Days Inn Monticello

LA Graphics

War Eagle Boats

Mr. Bug

Pines Broadcasting Company

ESA Staffing

Delta Memorial

Gibson & Keith

UAM News

UAM Sports

Commercial Bank

Ryburns

LifeShare No Date

Secure Storage 2

Western Sizzlin

Frazers Funeral Home

OFallon Vet

Key Employment Inc

Bakers Electrical

NorthSide Baptist Church

Cash Saver Food Outlet

Head of the Class

Johnsons Showroom Furniture

South Arkansas Business Solutions

Ashley County Medical Center 2

Immanuel Baptist Church

Southern Quality Construction

L to R: Jane Pelkki, Registered Dietitian and Brenda Jacobs, DNP, APRN and CEO, both with Daughters of Charity Services of Arkansas, show some teaching tools used in diabetes classes.

Free diabetes classes are being offered at Holmes Chapel Presbyterian Church beginning on Tuesday, April 11 from 11 am until 1 pm.

These classes are offered to anyone who wants to learn more about healthy eating, blood sugar control, diabetes medicines and preventing diabetes complications.

Classes will be lead by Jane Pelkki, a local registered dietitian and Tia Reid, a local registered nurse. Classes are sponsored by Daughters of Charity Services of Arkansas.

People who have recently completed these classes had questions like these: Can I eat spaghetti or noodles? What should my blood sugar be after I eat? My doctor says that I need to go on insulin. What did I do wrong? Everyone got their questions answered and went home understanding more about caring for diabetes.

A free healthy meal will be served at each class and door prizes will be given away. A different topic will be discussed each time the class meets and participants are encouraged to come to as many classes as possible. The class schedule is Tuesday, 4/11 Diabetes myths and facts; Tuesday, 4/18 Healthy eating with diabetes; Tuesday, 5/2 Blood sugar control; Tuesday, 5/9 Medicines and preventing complications.

For more information, call Daughters of Charity Services of Arkansas at 870-382-4878, extension 3830.

This entry was posted on Monday, April 10th, 2017 at 12:37 am and is filed under Announcements. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

The Guest House

Monticello Tire (Goodyear)

DMH Job Listing 1-3-17

Razorback Body Shop

A.J. Huffman

Mt. Tabor

Ray Ryburn Real Estate

Monticello Animal Clinic

Monticello Realty

SEEMS

Bradley County Medical Center

Wing Tip Gear Dumas, AR

Advertise With Monticello Live

UAM

Bones Auto Parts

Greenscape Nursery

Holiday Inn Express

State Farm Mark Gray

Reggies Lock & Key

PDQ Inc.

Ashley County Medical Center

Farmers Insurance

Citizens Bank

Ashley County Medical Center 3

Cass Martin Realty

Malco Theater

Fuller Lawn & Garden

ASFCU

Atlas Foundation Repair

Farm Bureau

Union Bank 2

Jerry Cruce Stump Grinding

City Drug

Drew Farm / Drew Outdoor & Casual Wear

The Computer Guys

Read the original post:
Free Diabetes Classes at Holmes Chapel, Start Tuesday - Monticello Live

Posted in Diabetes | Comments Off on Free Diabetes Classes at Holmes Chapel, Start Tuesday – Monticello Live

Erie teen with diabetes missing, at risk of having serious health … – The Denver Channel

Posted: April 10, 2017 at 7:40 am

ERIE, Colo. A diabetic teen in Erie has gone missing and police are asking for your help to find her.

Patience Lee Thompson, 16, was reported as a runaway from her home in the area of Moffat and Main Streets at around 1:09 a.m. Saturday.

Thompson was last seen at 11:45 p.m. by her sister, Erie police said in a news release.

Thompson is a Type-1 diabetic and takes a dose of insulin every 24 hours, but police said she may not have enough to meet her daily requirements, adding the dose she took with her would be only be used if her sugar levels were outside of her normal level during the day.

She is described as 5-feet-5 tall, weighing approximately 140 pounds. She has shoulder-length brown hair and blue yes. She was last seen wearing a black hooded sweatshirt and black sweat pants with two white strips on one leg.

Patience has likely been more than 24 hours without her daily dose of insulin and is at-risk for serious health problems, police said in a statement.

Anyone with information as to her whereabouts is asked to call Erie Police through the Boulder County Dispatch at (303) 441-4444.

Enjoy this content? Follow Denver7 on Facebook, Twitter, Instagram and download the Denver7 app on iOS and Android devices for continual access to breaking news, weather and sports.

Read more from the original source:
Erie teen with diabetes missing, at risk of having serious health ... - The Denver Channel

Posted in Diabetes | Comments Off on Erie teen with diabetes missing, at risk of having serious health … – The Denver Channel

Fears grow for nine-year-old girl with severe diabetes after disappearance from London hospital – The Independent

Posted: April 10, 2017 at 7:40 am

Fears are mounting for the safety of a sick nine-year-old girl who went missing after being taken to hospital in need of urgent medical care.

The Metropolitan Police has issued a plea for information after girl vanished from St Mary's hospital in Paddington, London, shortly after arriving to see medics on Sunday evening.

Scotland Yard said the girl attended the hospital accompanied by her parents and a younger brother at around 5.40pm after she fell ill.

But the family left two hours later before the girl, who police believe is diabetic, could receive treatment.

Police said the girl had a high blood sugar count, meaning she could fall into a coma if she is not treated.

A police statement said: The girl was initially seen by medical staff and her parents informed them that their child's name was Mashael Aldosari.

Detectives are unsure if this is the child's real name as the family provided a false address to staff.

Police know very little about the family as the adults did not provide their names to staff at the hospital. All four left the hospital at 7.44pm.

At this early stage detectives believe that the family could be from Kuwait.

The family are believed to have told medical staff that they had travelled to the UK in order for their son to receive hospital treatment. Inquiries have established that this is may not be the case.

It is not known when the family entered the country and inquires continue with other agencies.

Given the circumstances, detectives are urgently seeking the trace the young girl in order for her to receive medical treatment.

Mashael is described as being less than 5ft and has long, straight black hair. She was last seen wearing a grey top, leggings and light coloured shoes.

The man is described as having a heavy build and has short black hair receding at the front.

The woman was wearing a black burka.

Anyone with information is asked to contact police.

Press Association

Originally posted here:
Fears grow for nine-year-old girl with severe diabetes after disappearance from London hospital - The Independent

Posted in Diabetes | Comments Off on Fears grow for nine-year-old girl with severe diabetes after disappearance from London hospital – The Independent

Australian of the Year Alan Mackay-Sim on the advantage of being ‘an interested scientist’ – The Sydney Morning Herald

Posted: April 9, 2017 at 2:45 am

Suspended from a tree in the wilds of Tennessee, the remains of his hang-glider entangled in the branches above, his lower left leg pulverised and his chest badly bruised from his dramatic fall into the forest canopy, Alan Mackay-Sim felt hyper-alert from the electricity of adrenalin, the clarity of shock. Only the wind was audible, softly rustling the branches around him as he sucked in the forest air, perfumed with poplar and sweet-gum.

Knowing that the adrenalin coursing through his veins would soon give way to an agonising and possibly debilitating pain, the 28-year-old used these precious minutes to assess his predicament, to figure it out coolly like a man of science.

A broken leg, no doubt shattered in multiple places. Possibly hours before his fellow hang-gliding friends would be able to locate him; if they didn't reach him by nightfall, he could be dangling here until the next morning. Unfastening his harness and climbing down to the ground five metres below was not an option, at least, not without incurring further injury. To prevent blood from pooling and to save his leg, he quickly concluded, he'd have to carefully oh-so carefully free the hang-glider's stirrup bar and one of the ropes from his harness, create a splint for his injured left leg, secure it to his right leg and hoist up both limbs while hanging there like a gammy fruit bat.

Mackay-Sim had only arrived in the US a few weeks before, a post-doctoral researcher from the University of Sydney eager to extend his studies into the olfactory system specifically, what the nose tells the brain at the University of Philadelphia. But on that blustery October day back in 1979, when a freak wind gust whooshing around Lookout Mountain near Chattanooga sent a promising young Australian scientist nosediving into the forest, before a rescue team found himhanging in the tree just before sunset, both legs securely elevated, Mackay-Sim was set to gain some useful insights that would become valuable to him in his later life. Insights that would be peculiarly relevant to his work as a pioneering stem cell researcher specialising in the treatment of spinal cord injuries.

So badly broken was his leg that Mackay-Sim spent more than six months in a wheelchair, and many more months afterwards receiving intensive physiotherapy.

"It gave me some insight into what life's like in a wheelchair, and it stayed with me," says Mackay-Sim, settling into a chair in his office at the Institute for Drug Discovery at Griffith University, just down the corridor from the laboratory where he spent years toiling over petri dishes of nasal stem cells, in his life's mission to treat spinal injuries, hereditary spastic paraplegia and diseases like Parkinson's.

A photo of the late actor Christopher Reeve is pinned on a noticeboard behind him. "I met Christopher in 2003 when he came out for a conference; he was interested in our clinical trials," Mackay-Sim says, looking at the photo. "Then in the following year I spent some time at his home in New York, and we talked a lot about spinal cord injury repair, and his own personal story."

As Mackay-Sim explains, the higher up the spinal cord an injury is, the more severe the effects. "As we know, Christopher fell off a horse and became a full paraplegic on a respirator, but in fact he suffered only a small injury; the problem was that the bleed went straight into his spinal cord. It only takes a very small injury to stop transmission; you can have large injuries to the chest and not suffer long-term repercussions but here, in the neck, a small event can change your life."

Back in the late 1980s, after he started at Griffith University, Mackay-Sim became interested in a set of extraordinary busy-bee cells in the human nose called olfactory ensheathing cells nerve cells that regenerate every single day to recreate our sense of smell. If these wonder cells are continually regenerating, he kept asking himself, could they not be transplanted to another part of the body where cells don't regenerate, like the spinal cord?

Years of scientific slog followed until 2002, when Mackay-Sim was the first researcher in the world to remove cells from the nose of a patient paralysed in a car accident, grow them in a cell culture and then, with the help of surgeons at Brisbane's Princess Alexandra Hospital, implant them in the same patient's spinal cord. "By the time Christopher died in 2006, we'd transferred stem cells from the nose into three patients and shown it was safe to do so," he says. "One of the patients recovered some sensation above the injury, which was hopeful, but one person does not make real scientific evidence."

For Mackay-Sim, the importance of scientific breakthroughs in the treatment of life-threatening illnesses is deeply personal. In 2014, he was diagnosed with multiple myeloma, an incurable form of leukaemia. As a result of the illness, which breaks down bones in an advanced form of osteoporosis, and the punishing series of treatments that followed his diagnosis, involving radiation, chemotherapy and stem cell therapy (albeit a very different form from the one the scientist was researching), Mackay-Sim lost nine centimetres in height and shed more than 15 kilograms of body weight. "I became extremely sick from the chemotherapy just prior to the bone marrow transplant," the 65-year-old recalls. "It was the worst experience of my life."

There was also the initial shock of the diagnosis, and grief for the loss of his health after a highly active life, from football and rowing in his teens to distance cycling, scuba diving and hang-gliding, which he took up while atuniversity. "Both my parents lived into their 80s and 90s and I'd been cycling up to 200 kilometres a week for decades, so I wasn't anticipating something like this."

Still, as a scientist he couldn't help but observe the trajectory of his illness with stricken fascination. "I had some good conversations with my oncologist," he smiles. "As a biologist examining my own biology, it did demystify lots of things. One minute I was a grieving patient, the next an interested scientist."

Above all, Mackay-Sim refuses to sentimentalise his battle with the illness and asks that I don't embroider it in this story by turning it into some kind of triumph of personal will power over disease. "My survival is determined by the vagaries of the particular cancer I've got," he says matter-of-factly. "Some people have nasty genetic diseases that mean they die earlier. For the moment, I feel very healthy."

Surely his extreme fitness at least helped him to survive the ravages of chemo? "I think being fit and active all my life has given me a higher quality of life after treatment," he acknowledges. "But one doctor put it to me that I probably would have sought out treatment earlier if I wasn't so fit, because I dismissed the symptoms as simple back pain from the cycling. It took two years after the chemo and radiation for the pain to go away. 2016 was a year of normality for me my back became stable enough for me to get on a road bike again."

The diagnosis added poignancy to the evening in Canberra in late January when Mackay-Sim, out of 3000- plus nominations, was crowned Australian of the Year. Sitting alongside him were his American-born wife of nearly 34 years, Lisa Peine, a retired primary school teacher, their 28-year-old daughter Matilda, a trainee psychiatrist, and 25-year-old son Callum, an engineer.

Mackay-Sim with wife Lisa Peine in North Queensland in 1983. Photo: Courtesy of Alan Mackay-Sim

Perhaps no Australian of the Year is better placed to recognise just how precious a year can be, and more determined to seize the moment to put science and innovation at the top of the national conversation. A former Queenslander of the Year, Mackay-Sim sees science as vital to our future national wellbeing, especially after the recent wake-up call in international school education rankings, which placed Australia behind Kazakhstan and Slovenia in maths and science.

Mackay-Sim agrees unequivocally with Michelle Simmons, professor of quantum physics at the University of NSW, who drew headlines recently when she declared that the "feminised" nature of Australia's high school physics curriculum (emphasising the sociology of science with essays and theory instead of rigorous lab experiments and mathematical problem-solving) had been an unmitigated failure. Introduced in the 1980s, the approach had resulted in a long, slow decline in standards.

"Scientific understanding comes from learning the processes; it can be hard work but is absolutely essential," Mackay-Sim insists. "The key to a good science education in schools is to get well-trained teachers." (Mackay-Sim has been deeply encouraged by some of the science teachers he's met since winning the award.)

The choice of Mackay-Sim the first scientist honoured as Australian of the Year since immunologist Ian Frazer in 2006 was met with near-universal applause by Australia's scientific community, who no doubt feel dispirited in this post-truth world of climate-change denial, cuts to the CSIRO and the growing view by government agencies that basic research isn't worth it.

"We need to invest in young scientists," Mackay-Sim declared in his acceptance speech, adding that the discovery of new medical treatments can reduce the strain on health budgets. "More than 10,000 Australians live with a spinal cord injury a new person is added to this tally every day." But politicians need to take a long-term view of the benefits of basic research, he tells me, "a view much longer than the political horizon".

The announcement also gave the image of the Australian of the Year awards a much-needed polish. The 2016 winner, Lieutenant-General David Morrison, drew criticism for charging up to $15,000 a pop forpublic speaking engagements, as well as grandstanding about sexism in the military despite his own handling of the army's "Jedi Council" sex scandal, in which demeaning sex videos of women were distributed among a group of soldiers. (It was revealed that Morrison's office knew of the scandal 11 months prior to the former Chief of Army releasing a now-famous condemnation on YouTube of those involved.)

Will Mackay-Sim accept speakers' fees? "I knew nothing about speakers' fees when I accepted the award," he says crisply. "I'm not pursuing money after all, I've spent my life doing public research."

Although he hasn't received any fees to date, Mackay-Sim insists that if they are offered, the funds will be donated to the Hereditary Spastic Paraplegia Research Foundation, his charity of choice.

Mackay-Sim only had a day or so to bask in the glow of being named Australian of the Year before there was a claim his scientific achievements had beenoverstated in the application. A Polish scientist, Professor Pawel Tabakow, after being approached by an Australian journalist in Europe, declared that Mackay-Sim had nothing to do with the world-first surgery using olfactory stem cells that enabled a Polish paraplegic, Darek Fidyka, to walk again. "It is not our business who should be Australian of the Year," Tabakow told The Weekend Australian. "But it is our business when his work is being linked to the surgery of Fidyka. He has no link whatsoever."

The scientific hullaballoo arose from the submission to the Australia Day Council (ADC), which states that Mackay-Sim's research "helped play a central role in proving the safety of science that was a precursor to Dr Tabokow in Poland undertaking the first successful restoration of mobility in a quadriplegic man".

Although Mackay-Sim didn't write the submission to the ADC, doesn't know who did, and never claimed to be involved in Tabokow's work, an artificial straight line was drawn between the two scientists, especially when the word "precursor" was dropped from condensed versions of the ADC's quote in multiple news stories (we'll examine the fallout from the controversy a little later).

Padding amiably about his large, multi-room laboratory, past refrigerator-sized storage cabinets containing cell cultures, past white-coated scientists peering into microscopes, Mackay-Sim seems to be in his element, with every second person saying "Hi", "Hello", or "How are you?" If stem cells are indeedthe microscopic building blocks of the world, this is the tiny universe the scientist feels most comfortable in. But it's a laboratory that now has to hum along without him Mackay-Sim retired late last year, his duties now limited to popping into the university once a week as an emeritus professor.

Later in the day, Professor George D. Mellick, head of Clinical Neurosciences at Griffith, tells me that Mackay-Sim has always set aside time to mentor younger scientists, and to explain sometimes hideously complicated science to a lay audience, but would be the last person to crow about his own scientific achievements.

"One of the things that isn't highlighted very much about Alan's work is his research into Parkinson's. We've been able to learn a lot about Parkinson's by studying cells from people with the disease, and the information coming out of this research will hopefully lead to better treatments."

Back in his office, Mackay-Sim gives me a quick rundown, 101-style, on the human nose. No, the human sense of smell doesn't necessarily decline with age, unless illness or disease set in, and it is astonishingly adept at distinguishing hundreds of thousands of different odours. Yes, women do have a superior sense of smell to men, but the difference is surprisingly only slight. Yes, the first symptom of Parkinson's, before the typical tremors set in, is a reduced sense of smell, as it is with those sufferers who will go on to develop dementia. And yes paws down dogs do have a vastly more powerful sense of smell than humans, although it's impossible to quantify by exactly how much (Mackay-Sim has been known to hide from his spoodle Henry, to measure how long it takes for the dog to find him).

As he relays all this, Mackay-Sim's eyes twinkle and a smile lights up his face: it's easy to see how he'd be the perfect academic for Griffith to call on to schmooze a government minister or potential philanthropist and secure desperately sought-after funding. I ask him about his trademark moustache, which he's had since the early 1990s, when he shaved off a beard. "My wife wouldn't recognise me without it," he jokes. "She says that a small mammal could roost beneath my mouth."

Mackay-Sim, whose double-barrelled surname comes from his paternal grandfather, grew up in middle-class Roseville, on Sydney's leafy North Shore, the third of four brothers. His mother Lois was a nurse during World War II and later a full-time mum while his father Malcolm ran a hardware importing and distributing business, Macsim Distributors (now Macsim Fasteners, owned by Alan's eldest brother, Fraser). At North Sydney Boys' High he was "the opposite of a shit-stirrer. I was vice captain, head of the cadets, played football, was in the rowing team, had a shot at athletics, sang in the choir I did it all."

With wife, Lisa Peine, in Sulawesi, Indonesia, 2007. Photo: Courtesy of Alan Mackay-Sim

After graduating with honours in science from Macquarie University, Mackay-Sim picked up tutoring work in the department of physiology at the University of Sydney, where he completed a PhD on the brain's visual system. Two academic stints in the US followed, first at the University of Pennsylvania from 1979 until 1981, followed by two years at the University of Wyoming, during which time he met his wife Lisa, then living in northern Colorado.

The pair married in 1984, by which time Mackay-Sim had been offered a research role in the department of physiology at the University of Adelaide. He started at Griffith University in 1987, where his research concentrated on the biology of nasal cells.

At the height of the heated moral debate over the use of embryonic stem cells whether the therapeutic potential of stem cells could justify destroying human embryos to extract them Mackay-Sim met Pope Benedict XVI at a Vatican conference in 2005. The Pope congratulated him on his exclusive use of adult stem cells.

"I wasn't avoiding embryonic stem cells for religious reasons," Mackay-Sim explains. "It just so happenedthat I was working with adult stem cells at the time and the conference was looking at alternatives to using embryonic stem cells. But it was a scientific conference and I was impressed with its calibre; the only difference was that men in purple robes were sitting at the back asking questions."

Later in the same trip, Mackay-Sim was invited, along with a host of others, to the Apostolic Palace at Castel Gandolfo the Vatican summer palace. "You feel the history of the Roman Catholic Church, with the Pope coming in with his cardinals and the Swiss Guards," he says. "I'm not a believer, but it was a very powerful experience."

In 2006, the debate over embryonic stem cells virtually vanished when scientist Shinya Yamanaka from Japan's Kyoto University stunned the world by proving that stem cells needn't come from human embryos adult cells can be reprogrammed to act like stem cells, to be returned to an embryo-like state (Yamanaka's discovery won him the Nobel Prize in 2012). "Yamanaka worked out how to genetically engineer any cells so that they had the properties of embryonic stem cells," says Mackay-Sim, who nonetheless continued to focus on adult stem cells only.

Mackay-Sim accomplished his own world first in 2002 when, with the assistance of doctors at Brisbane's Princess Alexandra Hospital, he transplanted olfactory stem cells into the spinal cord of a man crippled in a car accident. The procedure was repeated with two other paraplegic patients at the same hospital and the study wrapped up in 2007.

While the procedures didn't result in any of the patients regaining useful movement in their legs, the results of Mackay-Sim's clinical trials, published in 2005 and 2008, paved the way for further development of olfactory stem cell transplantation.

One researcher who followed Mackay-Sim's trials closely was Geoffrey Raisman from University College London, who visited the Australian team shortly after the first operation in Brisbane to study their work. Raisman later led the British team who worked with Polish surgeon Tabakow on Darek Fidyka in 2012.

Tabakow deployed 100 separate micro-injections of olfactory sheathing cells above and below Fidyka's spinal injury, with the hope these cells would provide a skeleton for nerve fibres to grow and reconnect. A former volunteer firefighter, Fidyka had become paralysed in 2010 after a severe knife attack by the jealous ex-husband of his girlfriend. The repeated stab wounds to Fidyka's back severed his spinal cord, paralysing from the waistdown. (Fidyka's attacker, a fellow firefighter, committed suicide shortly afterwards.)

There's no doubt Tabakow's work was a major advance on Mackay-Sim's research. Tabakow's strategy was to extract ensheathing cells specifically from the olfactory bulbs in Fidyka's nose, grow them in a culture, while also extracting nerve cells from his ankle in a multi-pronged attempt at spinal cord reconstruction. After a series of operations, Fidyka can walk with the assistance of a frame, has regained some bladder control and sexual function, and can ride a tricycle.

Raisman described their new stem cell procedure as "more impressive than man walking on the moon", but it will have be tested on other paraplegics, including those with more severe injuries than Fidyka's, such as car accident victims who have had more of their spinal cord damaged, before it can be declared a reliable method of restoring mobility. As impressive as Tabakow's achievement is, it has still only worked on one patient.

Nobody, however, disputes Mackay-Sim's immense contribution to stem cell transplantation; his work is unimpeachable. If nothing else, he was at the forefront of the science showing that restoring the ability to walk to paraplegics is no longer science fiction. "What I've always said is that we did the first phase of clinicaltrials with olfactory stem cells, and the aim of those trials was to show they were safe," says Mackay-Sim. "That was the first important step."

Mackay-Sim wrote to Tabakow shortly after the controversy blew up, explaining that he didn't write the submission to the Australia Day Council, and was in no way claiming credit for Fidyka's remarkable recovery. "He wrote back a very nice email," says Mackay-Sim. "I believe I've given credit to other scientists in every interview I've given to journalists. I feel comfortable in my behaviour and ethics."

With Prime Minister Turnbull in January this year. Photo: Elesa Kurtz

Mackay-Sim can remember the day when he felt something was wrong terribly wrong. He'd been suffering back pain for months, but dismissed it as old age, or strain from bending over on his bicycle on long rides, and stocked up his pantry with painkillers. "I was in Colorado with Lisa visiting her family, and the pain became so bad I couldn't walk very far. I found the pain eased when I got on my bicycle. I flew home a week before she did; the plane trip back was absolute hell."

What followed was a swift diagnostic journey from his GP to specialists at Brisbane's Wesley Hospital, resulting in a devastating diagnosis. "They suspected something cancerous quite quickly. I didn't realise how ill I was; by this stage, my kidneys weren't coping at all with the antibodies released from my white blood cells, which were going berserk trying to fight the disease. I was at risk of kidney failure and my bones were becoming very fragile. I started therapy almost immediately, in June 2014. Then began the cycles of chemotherapy and stem cell treatment in December."

Since the beginning of last year, however, Mackay-Sim's health has dramatically improved, and even though he's retired to his beachside home in Currimundi on the Sunshine Coast, he is still active in university affairs. He concedes that his health may prevent him from being as active as Rosie Batty, perhaps our most vigorous Australian of the Year to date. But he's already spoken at functions in Brisbane, Sydney and Perth, and will be attending the national March for Science on April 22, which coincides with Earth Day. He moves with the speed and fluidity of a man 10 or 15 years younger.

"I feel very healthy, very energised at the moment," says Mackay-Sim, who is planning a bicycle ride in Italy's Dolomites in July with a couple of mates. (Last year he and his wife went on the Great Victorian Bike Ride, a seven-day ride averaging 85 kilometres a day.)

"I do need to be selective with the number of invitations around Australian of the Year," he concedes, "but I'll do everything I can. After all, what more exciting time could you have to talk about science?"

Continued here:
Australian of the Year Alan Mackay-Sim on the advantage of being 'an interested scientist' - The Sydney Morning Herald

Posted in Colorado Stem Cells | Comments Off on Australian of the Year Alan Mackay-Sim on the advantage of being ‘an interested scientist’ – The Sydney Morning Herald

Gordon Research Conferences – 2017 Meeting – Stem Cells …

Posted: April 9, 2017 at 2:44 am

Sunday 4:00 pm - 8:00 pm Arrival and Check-in 6:00 pm Dinner 7:30 pm - 7:40 pm Welcome / Introductory Comments by GRC Site Staff 7:40 pm - 9:30 pm Keynote Session: Cancer Initiation Discussion Leader: Allison Bardin (Genetics and Developmental Biology Unit (INSERM U934), Institut Curie, France) 7:40 pm - 7:50 pm Opening Remarks 7:50 pm - 8:25 pm Ronald Depinho (University of Texas MD Anderson Cancer Center, USA) "Targeting Cancer Specific Vulnerabilities" 8:25 pm - 8:40 pm Discussion 8:40 pm - 9:15 pm Hans Clevers (Hubrecht Institute, The Netherlands) "Lgr5 Stem Cell-Grown Organoids and Their Applications" 9:15 pm - 9:30 pm Discussion Monday 7:30 am - 8:30 am Breakfast 9:00 am - 12:30 pm Stem Cell Biology Discussion Leader: Sean Morrison (University of Texas Southwestern Medical Center, USA) 9:00 am - 9:30 am Hans-Reimer Rodewald (German Cancer Research Center (DKFZ), Germany) "Resolving Hematopoiesis by Endogenous Barcoding" 9:30 am - 9:40 am Discussion 9:40 am - 10:10 am David Traver (University of California, San Diego, USA) "Development of Hematopoietic Stem Cells" 10:10 am - 10:20 am Discussion 10:20 am - 10:50 am Coffee Break 10:50 am - 11:20 am Leanne Jones (University of California, Los Angeles, USA) "Evolution of Stem Cell-Niche Interactions During Aging" 11:20 am - 11:30 am Discussion 11:30 am - 12:00 pm Helen Blau (Stanford University, USA) "Rejuvenation of Muscle Stem Cell Function" 12:00 pm - 12:10 pm Discussion 12:10 pm - 12:25 pm Selected from Poster Abstracts: John Schell (University of Utah, USA) "Limiting Mitochondrial Pyruvate Entry Alters Intestinal Stem Cell Maintenance and Proliferation" 12:25 pm - 12:30 pm Discussion 12:30 pm Lunch 1:30 pm - 4:30 pm Free Time 4:30 pm - 6:00 pm Poster Session 6:00 pm - 8:00 pm Genome Integrity Discussion Leader: Emmanuelle Passegue (Columbia University Medical Center, USA) 6:00 pm - 6:30 pm Andre Nussenzweig (National Cancer Institute, NIH, USA) "Endogenous and Exogenous DNA Breaks" 6:30 pm - 6:40 pm Discussion 6:40 pm - 7:10 pm Allison Bardin (Genetics and Developmental Biology Unit (INSERM U934), Institut Curie, France) "Spontaneous Somatic Stem Cell Mutations" 7:10 pm - 7:20 pm Discussion 7:20 pm - 7:50 pm Bjoern Schmacher (University of Cologne, Germany) "Non-Cell-Autonomous Regulation of the C. elegans p53 Response in Primordial Germ Cells" 7:50 pm - 8:00 pm Discussion 8:00 pm Dinner Tuesday 7:30 am - 8:30 am Breakfast 8:30 am Group Photo 9:00 am - 12:30 pm Epigenome Discussion Leader: Andre Nussenzweig (National Cancer Institute, NIH, USA) 9:00 am - 9:30 am Maarten Van Lohuizen (Netherlands Cancer Institute, The Netherlands) "Role of Polycomb Repressor Complex 2 in NSCLC: Consequences for Epigenetic Therapy" 9:30 am - 9:40 am Discussion 9:40 am - 10:10 am Anne Brunet (Stanford University, USA) "Mechanisms of Neural Stem Cell Aging" 10:10 am - 10:20 am Discussion 10:20 am - 10:50 am Coffee Break 10:50 am - 11:20 am Elaine Fuchs (Rockefeller University, USA) "Skin Stem Cells and Cancer: From Signaling to Chromatin Landscapes" 11:20 am - 11:30 am Discussion 11:30 am - 12:00 pm Thomas Rando (Stanford University, USA) "Epigenetic Determinants of Stem Cell Aging and Rejuvenation" 12:00 pm - 12:10 pm Discussion 12:10 pm - 12:25 pm Selected from Poster Abstracts: Francesco Neri (Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Germany) "Dnmt3b-Dependent Intragenic DNA Methylation Prevents RNA Polymerase II Spurious Entry on Gene Bodies and Cryptic Transcription Initiations" 12:25 pm - 12:30 pm Discussion 12:30 pm Lunch 1:30 pm - 4:30 pm Free Time 4:30 pm - 6:00 pm Poster Session 6:00 pm - 8:00 pm Stem Cell Niche and Environment Discussion Leader: Leanne Jones (University of California, Los Angeles, USA) 6:00 pm - 6:30 pm Valentina Greco (Yale University, USA) "Capturing the Interface Between Homeostasis and Cancer by Live Imaging" 6:30 pm - 6:40 pm Discussion 6:40 pm - 7:10 pm Sean Morrison (University of Texas Southwestern Medical Center, USA) "Metabolic Mechanisms Regulating Cancer Initiation" 7:10 pm - 7:20 pm Discussion 7:20 pm - 7:50 pm Amy Wagers (Harvard University, USA) "Muscle Stem Cells and Metabolism in Aging, Regeneration and Tumorigenesis" 7:50 pm - 8:00 pm Discussion 8:00 pm Dinner Wednesday 7:30 am - 8:30 am Breakfast 9:00 am - 12:30 pm Clonal Selection Discussion Leader: Andreas Trumpp (German Cancer Research Center / HI-STEM, Germany) 9:00 am - 9:30 am Catriona Jamieson (University of California, San Diego, USA) "The Role of RNA Processing Deregulation in Malignant Reprogramming" 9:30 am - 9:40 am Discussion 9:40 am - 10:10 am Douglas Winton (Cancer Research UK Cambridge Institute, United Kingdom) "Fate and Fidelity of Stem Cells in the Intestinal Epithelium" 10:10 am - 10:20 am Discussion 10:20 am - 10:50 am Coffee Break 10:50 am - 11:20 am Irving Weissman (Stanford University School of Medicine, USA) "Normal and Neoplastic Stem Cell Competitions" 11:20 am - 11:30 am Discussion 11:30 am - 12:00 pm Cedric Blanpain (Universite Libre de Bruxelles, Belgium) "Reprograming Stem Cells During Cancer Initiation" 12:00 pm - 12:10 pm Discussion 12:10 pm - 12:25 pm Selected from Poster Abstracts: Olivier Cinquin (University of California, Irvine, USA) "Quantification of In Vivo Progenitor Mutation Accrual with Ultra-Low Error Rate and Minimal Input DNA Using SIP-HAVA-seq" 12:25 pm - 12:30 pm Discussion 12:30 pm Lunch 1:30 pm - 4:30 pm Free Time 4:30 pm - 6:00 pm Poster Session 6:00 pm - 8:00 pm Stem Cell Metabolism and Signaling Discussion Leader: Helen Blau (Stanford University, USA) 6:00 pm - 6:30 pm Emmanuelle Passegue (Columbia University Medical Center, USA) "HSC, Metabolism and Fate Decisions" 6:30 pm - 6:40 pm Discussion 6:40 pm - 7:10 pm David Sabatini (Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, USA) "Regulation of Growth by the mTOR Pathway" 7:10 pm - 7:20 pm Discussion 7:20 pm - 7:50 pm Andreas Trumpp (German Cancer Research Center / HI-STEM, Germany) "Quiescence and Dormancy in Normal and Malignant Stem Cells" 7:50 pm - 8:00 pm Discussion 8:00 pm Dinner Thursday 7:30 am - 8:30 am Breakfast 8:30 am - 9:00 am Business Meeting Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair 9:00 am - 12:30 pm Plasticity and Heterogeneity Discussion Leader: Maarten Van Lohuizen (Netherlands Cancer Institute, The Netherlands) 9:00 am - 9:30 am Fred De Sauvage (Genentech, USA) "Targeting Intestinal Stem Cells in Cancer" 9:30 am - 9:40 am Discussion 9:40 am - 10:10 am Tannishtha Reya (University of California, San Diego, USA) "Stem Cell Signals in Cancer Heterogeneity and Therapy Resistance" 10:10 am - 10:20 am Discussion 10:20 am - 10:50 am Coffee Break 10:50 am - 11:20 am Christopher Heeschen (Barts Cancer Institute, Queen Mary University of London, United Kingdom) "Novel Precision Medicine Approaches for Pancreatic Cancer Stem Cells" 11:20 am - 11:30 am Discussion 11:30 am - 12:00 pm Henri Jasper (Buck Institute for Research on Aging, USA) "Control of Intestinal Stem Cell Activity: Lessons from Drosophila" 12:00 pm - 12:10 pm Discussion 12:10 pm - 12:25 pm Selected from Poster Abstracts: Jagdeep Nanchahal (University of Oxford, United Kingdom) "HMGB1 Accelerates Regeneration of Multiple Tissues by Transitioning Stem Cells to G(Alert)" 12:25 pm - 12:30 pm Discussion 12:30 pm Lunch 1:30 pm - 4:30 pm Free Time 4:30 pm - 6:00 pm Poster Session 6:00 pm - 8:00 pm Keynote Session: Developmental Pathways Discussion Leader: Hans-Reimer Rodewald (German Cancer Research Center (DKFZ), Germany) 6:00 pm - 6:15 pm Selected from Poster Abstracts: Ana Carolina Dantas Machado (University of Southern California, USA) "Mechanisms of Protein-DNA Recognition Provide Insights into Gene Regulation" 6:15 pm - 6:20 pm Discussion 6:20 pm - 7:00 pm Margaret Goodell (Baylor College of Medicine, USA) "Aging HSCs and Epigenetic Modulation" 7:00 pm - 7:10 pm Discussion 7:10 pm - 7:50 pm Manuel Serrano (Centro Nacional de Investigaciones Oncologicas, Spain) "Tissue Repair: An Integrative View of Senescence and Reprogramming" 7:50 pm - 8:00 pm Discussion 8:00 pm Dinner Friday 7:30 am - 8:30 am Breakfast 9:00 am Departure

Read more:
Gordon Research Conferences - 2017 Meeting - Stem Cells ...

Posted in California Stem Cells | Comments Off on Gordon Research Conferences – 2017 Meeting – Stem Cells …

UCLA develops artificial thymus that produces cancer-fighting cells – University of California

Posted: April 9, 2017 at 2:44 am

UCLA researchers have created a new system to produce human T cells, the white blood cells that fight against disease-causing intruders in the body. The system could be utilized to engineer T cells to find and attack cancer cells, which means it could be an important step toward generating a readily available supply of T cells for treating many different types of cancer.

The preclinical study, published in the journal Nature Methods, was led by senior authors Dr. Gay Crooks, a professor of pathology and laboratory medicine and of pediatrics and co-director of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and Amelie Montel-Hagen, an associate project scientist in Crooks lab.

The thymus sits in the front of the heart and plays a central role in the immune system. It uses blood stem cells to make T cells, which help the body fight infections and have the ability to eliminate cancer cells. However, as people age or become ill, the thymus isnt as efficient at making T cells.

T cells generated in the thymus acquire specialized molecules, called receptors, on their surface, and those receptors help T cells seek out and destroy virus-infected cells or cancer cells. Leveraging that process has emerged as a promising area of cancer research: Scientists have found that arming large numbers of T cells with specific cancer-finding receptors a method known as adoptive T cell immunotherapy has shown remarkable results in clinical trials.

Adoptive T cell immunotherapy typically involves collecting T cells from people who have cancer, engineering them in the lab with a cancer-finding receptor and transfusing the cells back into the patient.

However, adoptive T cell immunotherapy treatments can be time-consuming, and people with cancer might not have enough T cells for the approach to work, according to Dr. Christopher Seet, the studys first author and a clinical instructor who treats cancer patients in the division of hematology-oncology at UCLA.

Since adoptive T cell immunotherapy was first used clinically in 2006, scientists have recognized that it would be more efficient to create a readily available supply of T cells from donated blood cells or from pluripotent stem cells, which can create any cell type in the body. The challenge with that strategy would be that T cells created using this approach would carry receptors that are not matched to each individual patient, which could ultimately cause the patients body to reject the transplanted cells or could cause the T cells to target healthy tissue in addition to cancer cells.

We know that the key to creating a consistent and safe supply of cancer-fighting T cells would be to control the process in a way that deactivates all T cell receptors in the transplanted cells, except for the cancer-fighting receptors, Crooks said.

The UCLA team used a new combination of ingredients to create structures called artificial thymic organoids that, like the thymus, have the ability to produce T cells from blood stem cells. The scientists found that mature T cells created in the artificial thymic organoids carried a diverse range of T cell receptors and worked similarly to the T cells that a normal thymus produces.

Next, the team tested whether artificial thymic organoids could produce the specialized T cells with cancer-fighting T cell receptors. When they inserted a gene that delivers a cancer-fighting receptor to the blood stem cells, they found that the thymic organoids produced large numbers of cancer-specific T cells, and that all other T cell receptors were turned off. The results suggest that the cells could potentially be used to fight cancer without the risk of T cells attacking healthy tissue.

Montel-Hagen said the artificial thymic organoid can easily be reproduced by other scientists who study T cell development. The UCLA researchers now are looking into using the system with pluripotent stem cells, which could produce a consistent supply of cancer-fighting T cells for patients in need of immediate lifesaving treatment.

Kite Pharma holds a license to the artificial thymic organoid method, which is patented by the Regents of the University of California.

The research was supported by the National Institutes of Health (R01 AG049753, 1R21AI119927, P01 HL073104 and T32HL066992), Tower Cancer Research Foundation Career Development Award, the Prostate Cancer Foundation Challenge Award (15CHAL02) and a Jane Coffin Childs Postdoctoral Fellowship, as well as an Innovation Award and a Clinical Fellowship from the UCLA Broad Stem Cell Research Center.

Go here to see the original:
UCLA develops artificial thymus that produces cancer-fighting cells - University of California

Posted in California Stem Cells | Comments Off on UCLA develops artificial thymus that produces cancer-fighting cells – University of California

Page 1,609«..1020..1,6081,6091,6101,611..1,6201,630..»